突破性疗法-话题@MedSci

#突破性疗法#

77篇内容 | 2181人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1536221, encodeId=05361536221ed, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=不可手术腱鞘巨细胞瘤患者的福音！国内首个靶向创新药获突破性疗法认定, objectType=article, longId=733267, objectId=2ee2e33267bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ee2e33267bd, replyNumber=0, likeNumber=84, createdTime=2022-07-27, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ee2e33267bd, moduleTitle=不可手术腱鞘巨细胞瘤患者的福音！国内首个靶向创新药获突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ee2e33267bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536220, encodeId=429f1536220ae, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, objectType=article, longId=221117, objectId=796122111e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=796122111e42, replyNumber=0, likeNumber=74, createdTime=2021-11-28, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=796122111e42, moduleTitle=靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=796122111e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536219, encodeId=d16b153621989, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=FDA批准数字疗法产品作为老年性痴呆突破性疗法地位, objectType=article, longId=215742, objectId=8367215e42be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8367215e42be, replyNumber=0, likeNumber=85, createdTime=2021-08-16, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8367215e42be, moduleTitle=FDA批准数字疗法产品作为老年性痴呆突破性疗法地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8367215e42be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536218, encodeId=36831536218e1, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定, objectType=article, longId=210265, objectId=27f521026528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27f521026528, replyNumber=0, likeNumber=78, createdTime=2021-04-23, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f521026528, moduleTitle=安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f521026528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536217, encodeId=ff63153621e16, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=康方生物PD-1获FDA突破性疗法资格，三线治疗转移性鼻咽癌, objectType=article, longId=209532, objectId=d4c8209532bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4c8209532bd, replyNumber=0, likeNumber=92, createdTime=2021-04-05, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4c8209532bd, moduleTitle=康方生物PD-1获FDA突破性疗法资格，三线治疗转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4c8209532bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536216, encodeId=ac6f153621665, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=PFS 翻倍！tipifarnib获FDA突破性疗法资格, objectType=article, longId=207639, objectId=531020e6394d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=531020e6394d, replyNumber=0, likeNumber=83, createdTime=2021-02-28, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=531020e6394d, moduleTitle=PFS 翻倍！tipifarnib获FDA突破性疗法资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=531020e6394d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536215, encodeId=bd6b1536215c8, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, objectType=article, longId=207376, objectId=04bd20e376d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04bd20e376d9, replyNumber=0, likeNumber=88, createdTime=2021-02-22, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04bd20e376d9, moduleTitle=转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04bd20e376d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536214, encodeId=09941536214c5, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=中国国家药品管理局（NMPA）授予sotorasib治疗晚期非小细胞肺癌“突破性疗法称号”, objectType=article, longId=206441, objectId=d25f206441fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d25f206441fe, replyNumber=0, likeNumber=88, createdTime=2021-02-01, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d25f206441fe, moduleTitle=中国国家药品管理局（NMPA）授予sotorasib治疗晚期非小细胞肺癌“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d25f206441fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536213, encodeId=b84c153621314, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=治疗14天，1型糖尿病风险降低59%！突破性疗法teplizumab获FDA优先审评资格, objectType=article, longId=205577, objectId=44252055e715, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44252055e715, replyNumber=0, likeNumber=73, createdTime=2021-01-11, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44252055e715, moduleTitle=治疗14天，1型糖尿病风险降低59%！突破性疗法teplizumab获FDA优先审评资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44252055e715)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536212, encodeId=939d1536212dd, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=肿瘤疫苗+PD1，黑色素瘤患者完全缓解率45%！获得FDA突破性疗法认定, objectType=article, longId=204616, objectId=b52e2046165f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52e2046165f, replyNumber=0, likeNumber=91, createdTime=2020-12-19, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52e2046165f, moduleTitle=肿瘤疫苗+PD1，黑色素瘤患者完全缓解率45%！获得FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b52e2046165f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536211, encodeId=929415362118c, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号, objectType=article, longId=203543, objectId=df7b20354322, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df7b20354322, replyNumber=0, likeNumber=101, createdTime=2020-11-21, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df7b20354322, moduleTitle=ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df7b20354322)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536210, encodeId=98cf15362104c, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=Lanifibranor治疗NASH：FDA授予“突破性疗法称号”, objectType=article, longId=202052, objectId=b0b52020520a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0b52020520a, replyNumber=0, likeNumber=81, createdTime=2020-10-15, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0b52020520a, moduleTitle=Lanifibranor治疗NASH：FDA授予“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0b52020520a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536209, encodeId=1c1d153620953, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号, objectType=article, longId=201729, objectId=c1e7201e2955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e7201e2955, replyNumber=0, likeNumber=80, createdTime=2020-10-07, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e7201e2955, moduleTitle=IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e7201e2955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536208, encodeId=eeb3153620825, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=达格列净治疗慢性肾病获FDA突破性疗法认定, objectType=article, longId=201692, objectId=865a201692a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=865a201692a8, replyNumber=0, likeNumber=92, createdTime=2020-10-06, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=865a201692a8, moduleTitle=达格列净治疗慢性肾病获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=865a201692a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536207, encodeId=a9f8153620ef8, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, objectType=article, longId=201251, objectId=a8de201251f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8de201251f5, replyNumber=0, likeNumber=71, createdTime=2020-09-28, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8de201251f5, moduleTitle=FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8de201251f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536206, encodeId=1894153620629, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=荣昌生物纬迪西妥单抗（RC48）治疗尿路上皮癌获FDA突破性疗法认定, objectType=article, longId=201087, objectId=e72920108ee8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e72920108ee8, replyNumber=0, likeNumber=0, createdTime=2020-09-24, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e72920108ee8, moduleTitle=荣昌生物纬迪西妥单抗（RC48）治疗尿路上皮癌获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e72920108ee8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536205, encodeId=a303153620548, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=赛诺菲/再生元Dupixent获FDA突破性疗法认定, objectType=article, longId=200724, objectId=71cb200e24ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71cb200e24ec, replyNumber=0, likeNumber=93, createdTime=2020-09-17, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71cb200e24ec, moduleTitle=赛诺菲/再生元Dupixent获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71cb200e24ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536204, encodeId=f31c153620481, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=君实“特瑞普利单抗”：获得FDA突破性疗法认定的国产PD-1, objectType=article, longId=200557, objectId=49c220055e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49c220055e16, replyNumber=0, likeNumber=87, createdTime=2020-09-12, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49c220055e16, moduleTitle=君实“特瑞普利单抗”：获得FDA突破性疗法认定的国产PD-1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49c220055e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536203, encodeId=93691536203cf, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=万春医药First In Class新药普那布林获FDA突破性疗法认定, objectType=article, longId=200493, objectId=0b50200493e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b50200493e8, replyNumber=0, likeNumber=79, createdTime=2020-09-11, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b50200493e8, moduleTitle=万春医药First In Class新药普那布林获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b50200493e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536202, encodeId=7f3715362021d, content=<a href='/topic/show?id=75fbe553800' target=_blank style='color:#2F92EE;'>#突破性疗法#</a>, objectTitle=斑秃或有药可用！CTP-543获得FDA突破性疗法认定, objectType=article, longId=197300, objectId=0b5519e30035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b5519e30035, replyNumber=0, likeNumber=93, createdTime=2020-07-11, rootId=0, userName=zhwj, userId=7eca12667393, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b5519e30035, moduleTitle=斑秃或有药可用！CTP-543获得FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b5519e30035)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突破性疗法

2020-05-29

爆笑小医 (审核中...)

前往app查看评论内容

#突破性疗法#

不可手术腱鞘巨细胞瘤患者的福音！国内首个靶向创新药获突破性疗法认定

2022-07-27

爆笑小医 (审核中...)

前往app查看评论内容

#突破性疗法#

靶向HER2的抗体药物偶联物ENHERTU获得FDA授予突破性疗法称号，治疗HER2阳性转移性非小细胞肺癌

2021-11-28

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

FDA批准数字疗法产品作为老年性痴呆突破性疗法地位

2021-08-16

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

安进创新胃癌一线疗法bemarituzumab获美国FDA突破性疗法认定

2021-04-23

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

康方生物PD-1获FDA突破性疗法资格，三线治疗转移性鼻咽癌

2021-04-05

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

PFS 翻倍！tipifarnib获FDA突破性疗法资格

2021-02-28

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

转移性葡萄膜黑色素瘤该如何治疗？FDA授予tebentafusp“突破性疗法称号”

2021-02-22

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

中国国家药品管理局（NMPA）授予sotorasib治疗晚期非小细胞肺癌“突破性疗法称号”

2021-02-01

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

治疗14天，1型糖尿病风险降低59%！突破性疗法teplizumab获FDA优先审评资格

2021-01-11

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

肿瘤疫苗+PD1，黑色素瘤患者完全缓解率45%！获得FDA突破性疗法认定

2020-12-19

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

ViiV两月一次长效注射剂cabotegravir用于预防HIV，获得FDA的突破性疗法称号

2020-11-21

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

Lanifibranor治疗NASH：FDA授予“突破性疗法称号”

2020-10-15

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号

2020-10-07

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

达格列净治疗慢性肾病获FDA突破性疗法认定

2020-10-06

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

FDA授予Disitamab Vedotin（RC48）治疗泌尿上皮细胞癌“突破性疗法称号”

2020-09-28

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

荣昌生物纬迪西妥单抗（RC48）治疗尿路上皮癌获FDA突破性疗法认定

2020-09-24

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

赛诺菲/再生元Dupixent获FDA突破性疗法认定

2020-09-17

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

君实“特瑞普利单抗”：获得FDA突破性疗法认定的国产PD-1

2020-09-12

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

万春医药First In Class新药普那布林获FDA突破性疗法认定

2020-09-11

zhwj (审核中...)

前往app查看评论内容

#突破性疗法#

斑秃或有药可用！CTP-543获得FDA突破性疗法认定

2020-07-11

科室
- - 订阅+
  - 更多科室
工具
服务